MER Stock Overview
Merck KGaA operates as a science and technology company in Germany.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for MER from our risk checks.
Merck KGaA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €228.30 |
52 Week High | €0 |
52 Week Low | €0 |
Beta | 0.67 |
1 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | n/a |
3 Year Change | 75.62% |
5 Year Change | 109.35% |
Change since IPO | 116.60% |
Recent News & Updates
Recent updates
Shareholder Returns
MER | CH Pharmaceuticals | CH Market | |
---|---|---|---|
7D | 0% | -0.08% | 0.2% |
1Y | n/a | 8.7% | -3.9% |
Return vs Industry: Insufficient data to determine how MER performed against the Swiss Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MER performed against the Swiss Market.
Price Volatility
MER volatility | |
---|---|
MER Average Weekly Movement | 0% |
Pharmaceuticals Industry Average Movement | 3.1% |
Market Average Movement | 3.5% |
10% most volatile stocks in CH Market | 7.1% |
10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: MER has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MER's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1668 | 62,908 | Belen Garijo Lopez | www.emdgroup.com |
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Merck KGaA Fundamentals Summary
MER fundamental statistics | |
---|---|
Market cap | €65.19b |
Earnings (TTM) | €2.82b |
Revenue (TTM) | €20.99b |
23.1x
P/E Ratio3.1x
P/S RatioIs MER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MER income statement (TTM) | |
---|---|
Revenue | €20.99b |
Cost of Revenue | €8.56b |
Gross Profit | €12.44b |
Other Expenses | €9.61b |
Earnings | €2.82b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
Earnings per share (EPS) | 6.50 |
Gross Margin | 59.23% |
Net Profit Margin | 13.45% |
Debt/Equity Ratio | 35.2% |
How did MER perform over the long term?
See historical performance and comparison